Analysts think KZIA stock price could increase by 252%
Nov 22, 2024, 12:25 PM
-45.39%
What does KZIA do
Kazia Therapeutics, based in Sydney, Australia, focuses on oncology drug development, with lead programs including Paxalisib for brain cancer and EVT801 for inhibiting tumor blood vessel growth. The company targets diseases like brain, renal, and liver cancers.
3 analysts think KZIA stock price will increase by 252.30%. The current median analyst target is $19.48 compared to a current stock price of $5.53. The lowest analysts target is $19.29 and the highest analyst target is $20.06.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
